Indication
Patients not adequately controlled with inhaled corticosteroids and as needed inhaled short acting beta-2-agonist or, Patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.
Dosage and Administration
Adults and adolescents 12 years and older : Salflu® -100 : One Rotacap twice daily.
Salflu® -250 : One Rotacap twice daily.
Salflu® -500 : One Rotacap twice daily.
Children 4 years and older : Salflu® -100 : One Rotacap twice daily.
Children aged under 4 years : Not recommended.
Adults and adolescents 12 years and older:
Two inhalations of Salflu® 125 HFA twice daily, or Two inhalations of Salflu® 250 HFA twice daily.
Composition
Salflu® 100 : Each capsule contains microfine Salmeterol (as Xinafoate) BP 50 mcg and microfine Fluticasone Propionate BP 100 mcg.
Salflu® 250 : Each capsule contains microfine Salmeterol (as Xinafoate) BP 50 mcg and microfine Fluticasone Propionate BP 250 mcg.
Salflu® 500 : Each capsule contains microfine Salmeterol (as Xinafoate) BP 50 mcg and microfine Fluticasone Propionate BP 500 mcg.
Salflu® 125 HFA : Each actuation delivers Salmeterol (as Xinafoate) 25 mcg & Fluticasone Propionate BP 125 mcg.
Salflu® 250 HFA : Each actuation delivers Salmeterol (as Xinafoate) 25 mcg & Fluticasone Propionate BP 250 mcg.